Anumana’s AI tool for pulmonary hypertension gets FDA breakthrough status

Related Articles
AI-guided Detection of Heart Disease in Routine Practice
Med India: Artificial intelligence (AI) screening helps detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published…May 08, 2021
Mayo Clinic platform aids clinical decisions
IMC Newsdesk: Mayo Clinic has developed health technology to deliver clinical decision support tools, diagnostic insights and care recommendations so clinicians can make faster and more accurate diagnoses and provide…April 19, 2021
Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection
Medtech Dive: Anumana, a health technology startup spun out of Mayo Clinic, entered a multi-year agreement with Pfizer to develop an algorithm to detect cardiac amyloidosis, a serious heart condition.…December 16, 2022
J&J Hired Thousands of Data Scientists. Will The Strategy Pay Off?
WSJ: One project—with the Mayo Clinic and a health-technology company called Anumana based in Cambridge, Mass.—aims to speed up diagnosis of high blood pressure in the lungs, or pulmonary hypertension.…November 30, 2023


